Analysts Offer Predictions for PBH Q3 Earnings

Prestige Consumer Healthcare Inc. (NYSE:PBH) – Investment analysts at DA Davidson issued their Q3 2025 EPS estimates for Prestige Consumer Healthcare in a note issued to investors on Monday, November 11th. DA Davidson analyst L. Weiser expects that the company will earn $1.16 per share for the quarter. DA Davidson currently has a “Buy” rating and a $95.00 target price on the stock. The consensus estimate for Prestige Consumer Healthcare’s current full-year earnings is $4.44 per share. DA Davidson also issued estimates for Prestige Consumer Healthcare’s FY2025 earnings at $4.46 EPS.

Separately, Jefferies Financial Group reiterated a “hold” rating and set a $76.00 price target (up from $70.00) on shares of Prestige Consumer Healthcare in a report on Tuesday, September 24th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $94.20.

Prestige Consumer Healthcare Price Performance

Shares of NYSE PBH opened at $81.75 on Tuesday. The firm has a market capitalization of $4.05 billion, a PE ratio of 19.89, a P/E/G ratio of 2.27 and a beta of 0.47. The company has a debt-to-equity ratio of 0.61, a current ratio of 3.56 and a quick ratio of 1.90. Prestige Consumer Healthcare has a 1-year low of $56.61 and a 1-year high of $82.00. The business’s fifty day moving average price is $72.55 and its two-hundred day moving average price is $69.84.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings data on Thursday, November 7th. The company reported $1.09 EPS for the quarter, meeting analysts’ consensus estimates of $1.09. The company had revenue of $283.79 million during the quarter, compared to the consensus estimate of $282.09 million. Prestige Consumer Healthcare had a net margin of 18.54% and a return on equity of 12.23%. The company’s quarterly revenue was down .9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.07 EPS.

Institutional Investors Weigh In On Prestige Consumer Healthcare

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Intech Investment Management LLC purchased a new stake in Prestige Consumer Healthcare in the 3rd quarter worth about $620,000. Quest Partners LLC lifted its position in Prestige Consumer Healthcare by 2,582.0% during the third quarter. Quest Partners LLC now owns 11,774 shares of the company’s stock valued at $849,000 after purchasing an additional 11,335 shares during the period. Natixis Advisors LLC increased its holdings in Prestige Consumer Healthcare by 11.4% in the third quarter. Natixis Advisors LLC now owns 14,581 shares of the company’s stock valued at $1,051,000 after buying an additional 1,491 shares in the last quarter. Huntington National Bank raised its position in shares of Prestige Consumer Healthcare by 39.9% in the third quarter. Huntington National Bank now owns 635 shares of the company’s stock valued at $46,000 after buying an additional 181 shares during the last quarter. Finally, MQS Management LLC purchased a new position in Prestige Consumer Healthcare during the third quarter worth about $552,000. 99.95% of the stock is currently owned by hedge funds and other institutional investors.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.